Publications by authors named "J Timbol"
Background: The 2023-2024 influenza season had predominant influenza A(H1N1)pdm09 virus activity, but A(H3N2) and B viruses co-circulated. Seasonal influenza vaccine strains were well-matched to these viruses.
Methods: Using health care encounters data from health systems in 8 states, we evaluated influenza vaccine effectiveness (VE) against influenza-associated medical encounters from October 2023-April 2024.
Article Synopsis
- - In 2014, the PCV13 vaccine was recommended for adults 65 and older, aiming to reduce invasive pneumococcal disease (IPD), yet cases of serotype 3 lingered despite overall declines in other serotypes.
- - A study conducted from 2014 to 2020 within Kaiser Permanente Northern California evaluated the effectiveness of PCV13 in preventing IPD in this age group, analyzing over 610,000 participants.
- - The findings showed that the vaccine was 61.5% effective against PCV13-serotype IPD and 46.3% effective against serotype 3, highlighting the need for ongoing monitoring of vaccine impact on IPD across different serotypes. *
Incidence and Risk of Coronavirus Disease 2019 Hospitalization Among Unvaccinated Children.
Influenza Other Respir Viruses
October 2024
Objectives: The aim of this study is to determine the incidence and risk factors associated with COVID-19 hospitalization among unvaccinated children.
Methods: Children aged 0- < 18 years, members of Kaiser Permanente Northern California (KPNC), were followed from March 1, 2020, until the earliest occurrence of: chart-confirmed COVID-19 hospitalization, disenrollment from KPNC, age 18 years, receipt of COVID-19 vaccine, death, or study end (December 31, 2022). We calculated the incidence rate of hospitalization by SARS-CoV-2 variant period and by age group.
Background: Respiratory syncytial virus vaccines first recommended for use during 2023 were efficacious against lower respiratory tract disease in clinical trials. Limited real-world data regarding respiratory syncytial virus vaccine effectiveness are available. To inform vaccine policy and address gaps in evidence from the clinical trials, we aimed to assess the effectiveness against respiratory syncytial virus-associated hospitalisations and emergency department encounters among adults aged at least 60 years.
View Article and Find Full Text PDFArticle Synopsis
- The 2022-2023 influenza season in the U.S. experienced high hospitalization rates and early influenza activity, primarily driven by A(H3N2) viruses, with some A(H1N1)pdm09 cases.
- A study using the test-negative design assessed the effectiveness of the influenza vaccine by comparing cases of influenza-positive patients to those who tested negative among adults with respiratory illness from October 2022 to March 2023.
- The results showed moderate vaccine effectiveness of 44% for emergency department visits and 35% for hospitalizations, indicating that vaccination helps reduce the impact of influenza during a challenging season with other circulating respiratory viruses.